Hvivo logo

HVOA - Hvivo Share Price

n/a 0.0  0.0%

Sector
Healthcare
Size
Market Cap £n/a
Enterprise Value £n/a
Revenue £n/a
Position in Universe th / 1816
Bullish
Bearish
Unlock HVOA Revenue
Momentum
Relative Strength (%)
1m
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 01st Jan 2013 2014 2015 2016 2017 2018 2019E 2020E CAGR / Avg
0.000 0.000 0.000 0.000 0.000 0.000
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the six months ended 30 June 2019, Hvivo PLC revenues increased 22% to £5.9M. Net loss decreased 13% to £3.8M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Research and development expense decrease of 60% to £1.1M (expense), Administrave expense decrease of 22% to £3.8M (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

HVOA Revenue Unlock HVOA Revenue

Net Income

HVOA Net Income Unlock HVOA Revenue

Normalised EPS

HVOA Normalised EPS Unlock HVOA Revenue

PE Ratio Range

HVOA PE Ratio Range Unlock HVOA Revenue

Dividend Yield Range

HVOA Dividend Yield Range Unlock HVOA Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
HVOA EPS Forecasts Unlock HVOA Revenue
Profile Summary

hVIVO plc, formerly Retroscreen Virology Group plc, is a holding company. The Company is engaged in a life sciences business pioneering a technology platform of human disease models to accelerate drug discovery and development in respiratory and infectious diseases, including flu, respiratory syncytial virus (RSV), asthma and common cold. It has commercialized approximately four disease models, enrolled over 2,000 subjects and conducted approximately 40 product validation studies for a range of industry, government and academic clients and collaborators. The Company offers services, such as challenge study services, lab services, and target and biomarker discovery. It offers viral challenge studies in healthy volunteers in influenza, human rhinovirus (HRV) and RSV. Its lab services include assay development, transfer and optimization across the immunological, molecular and cell-based assay platforms, including offering options in sample matrix testing and specialty biomarker assays.

Directors
Last Annual January 1st, 1970
Last Interim January 1st, 1970
Incorporated March 27, 2012
Public Since May 3, 2012
No. of Shareholders: n/a
No. of Employees: 139
Sector Healthcare
Industry Healthcare Providers & Services
Index
Exchange London Stock Exchange
Shares in Issue
Free Float (0.0%)
Eligible for
ISAs
SIPPs
HVOA Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for HVOA
Upcoming Events for HVOA
Similar to HVOA
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.